CASSIPA Drug Patent Profile
✉ Email this page to a colleague
When do Cassipa patents expire, and when can generic versions of Cassipa launch?
Cassipa is a drug marketed by Teva Pharms Usa and is included in one NDA.
The generic ingredient in CASSIPA is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cassipa
A generic version of CASSIPA was approved as buprenorphine hydrochloride; naloxone hydrochloride by ACTAVIS ELIZABETH on February 22nd, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CASSIPA?
- What are the global sales for CASSIPA?
- What is Average Wholesale Price for CASSIPA?
Summary for CASSIPA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | CASSIPA at DailyMed |
US Patents and Regulatory Information for CASSIPA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | CASSIPA | buprenorphine hydrochloride; naloxone hydrochloride | FILM;SUBLINGUAL | 208042-001 | Sep 7, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
